-
1
-
-
78649628169
-
FDA accelerated approval benefits glioblastoma
-
Cloughesy T. FDA accelerated approval benefits glioblastoma. Lancet Oncol 2010; 11: 1120.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1120
-
-
Cloughesy, T.1
-
3
-
-
77954720781
-
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
-
Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-23.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2817-2823
-
-
Batchelor, T.T.1
Duda, D.G.2
di Tomaso, E.3
-
4
-
-
77952523530
-
Bevacizumab salvage therapy following progression in high-grade gliomas patients treated with VEGF receptor tyrosine kinase inhibitors
-
Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade gliomas patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 2010; 12: 603-7.
-
(2010)
Neuro Oncol
, vol.12
, pp. 603-607
-
-
Scott, B.J.1
Quant, E.C.2
McNamara, M.B.3
Ryg, P.A.4
Batchelor, T.T.5
Wen, P.Y.6
-
5
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-9.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon 2nd, J.E.3
-
6
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-40.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
-
7
-
-
77952809712
-
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
-
Xu T, Chen J, Lu Y, Wolff JEA. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 2010; 10: 252.
-
(2010)
BMC Cancer
, vol.10
, pp. 252
-
-
Xu, T.1
Chen, J.2
Lu, Y.3
Wolff, J.E.A.4
-
8
-
-
68049093213
-
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
-
Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589-99.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4589-4599
-
-
Lucio-Eterovic, A.K.1
Piao, Y.2
de Groot, J.F.3
-
9
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Pàez-Ribes, M.1
Allen, E.2
Hudock, J.3
-
10
-
-
79952740612
-
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
-
Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011; 108: 3749-54.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 3749-3754
-
-
Keunen, O.1
Johansson, M.2
Oudin, A.3
-
11
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Pàez-Ribes, M.1
Allen, E.2
Hudock, J.3
-
12
-
-
38749147680
-
Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy
-
Okaji Y, Tsuno NH, Tanaka M et al. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer 2008; 44: 383-90.
-
(2008)
Eur J Cancer
, vol.44
, pp. 383-390
-
-
Okaji, Y.1
Tsuno, N.H.2
Tanaka, M.3
-
13
-
-
33646174504
-
Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy
-
Okaji Y, Tsuno NH, Saito S et al. Vaccines targeting tumour angiogenesis - a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32: 363-70.
-
(2006)
Eur J Surg Oncol
, vol.32
, pp. 363-370
-
-
Okaji, Y.1
Tsuno, N.H.2
Saito, S.3
-
14
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
15
-
-
84873722707
-
-
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 data files. [Cited 17 May 2010.] Available from URL:
-
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 data files. 2010 [Cited 17 May 2010.] Available from URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
-
(2010)
-
-
-
17
-
-
34447285771
-
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
-
Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007; 25: 2601-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2601-2606
-
-
Carson, K.A.1
Grossman, S.A.2
Fisher, J.D.3
Shaw, E.G.4
-
18
-
-
0033897173
-
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
-
Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93.
-
(2000)
Br J Cancer
, vol.83
, pp. 588-593
-
-
Yung, W.K.1
Albright, R.E.2
Olson, J.3
-
19
-
-
43249090418
-
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
-
Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108: 963-71.
-
(2008)
J Neurosurg
, vol.108
, pp. 963-971
-
-
Izumoto, S.1
Tsuboi, A.2
Oka, Y.3
-
20
-
-
78650153633
-
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
-
Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-8.
-
(2010)
Nature
, vol.468
, pp. 824-828
-
-
Ricci-Vitiani, L.1
Pallini, R.2
Biffoni, M.3
-
21
-
-
0028362876
-
Requirement of vascular integrin alpha v beta 3 for angiogenesis
-
Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
-
(1994)
Science
, vol.264
, pp. 569-571
-
-
Brooks, P.C.1
Clark, R.A.2
Cheresh, D.A.3
-
22
-
-
79960462574
-
Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy
-
Nassiri F, Cusimano MD, Scheithauer BW et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 2011; 31: 2283-90.
-
(2011)
Anticancer Res
, vol.31
, pp. 2283-2290
-
-
Nassiri, F.1
Cusimano, M.D.2
Scheithauer, B.W.3
|